Peptomyc
Vanessa Ortiz Barahona, PhD has a strong background in oncology research. Vanessa is currently working as a Postdoctoral Scientist at Peptomyc since December 2022. Prior to this, they worked as an Oncology Scientist at the Josep Carreras Leukaemia Research Institute from March 2020 to March 2022. Vanessa also served as an Oncology Scientist at the Bellvitge Biomedical Research Institute - IDIBELL from October 2016 to February 2020. In addition, they gained experience as a Visiting Research Scientist at CIC bioGUNE in February 2017. Vanessa further enhanced their research capabilities as a Research Associate at the Centre for Genomic Regulation (CRG) from October 2015 to July 2016, and at NYU Langone Health from February 2015 to August 2015. Prior to that, they worked as a Voluntary Research Assistant at Universidad Francisco de Vitoria from October 2013 to November 2014.
Vanessa Ortiz Barahona, PhD, completed their education in a chronological sequence. Vanessa began their academic journey in 2011 at Universidad Francisco de Vitoria, where they obtained a Bachelor's degree in Biotechnology in 2015. Following this, they pursued a Master's degree in Biomedicine at the Universitat de Barcelona from 2015 to 2016. Vanessa continued their studies at the same institution and achieved a Doctor of Philosophy (PhD) degree in Biomedicine from 2016 to 2022.
In addition to their formal education, Vanessa also obtained certifications to enhance their professional skills. In October 2022, they completed the ICH Good Clinical Practice E6 (R2) certification from The Global Health Network. Vanessa also obtained an Introduction to Data Management For Clinical Research Studies certification from the same institution in October 2022.
This person is not in the org chart
This person is not in any teams
Peptomyc
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.